文献速递类风湿关节炎

基线自身抗体优先影响生物制剂初治类风湿关节炎患者阿巴西普疗效:ACTION 研究 6 个月结果

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study.
PubMed 文献 · RMD Open · 2017-02-13

ACTION 研究纳入 672 例生物制剂初治的类风湿关节炎(RA)患者,比较基线类风湿因子(RF)和抗环瓜氨酸肽抗体(anti-CCP)状态与静脉阿巴西普 6 个月疗效的关系。结果显示 RF 阳性或 anti-CCP 阳性患者的 EULAR 反应率、平均 CDAI 和 Boolean 缓解均优于血清阴性患者。

要点

  • RF 阳性者 6 个月良好或中度 EULAR 反应率 84.6%,高于 RF 阴性者的 72.9%(p=0.012)。
  • anti-CCP 阳性者 EULAR 反应率 85.2%,高于阴性者的 74.2%(p=0.015)。
  • RF 阳性者 Boolean 缓解率 13.3%,高于阴性者的 4.0%(p=0.008)。

核心结论

  • 在生物制剂初治的 RA 患者中,RF 阳性和/或 anti-CCP 阳性与静脉阿巴西普疗效优于血清阴性状态相关。

研究设计与样本

  • ACTION 是一项真实世界、国际、前瞻性研究,纳入 672 例生物制剂初治的 RA 患者,按基线 RF 和 anti-CCP 状态比较 6 个月临床结局。

主要发现

  • 577 例(86%)报告 RF 状态,其中 412 例(71%)阳性;552 例(82%)报告 anti-CCP 状态,其中 364 例(66%)阳性。
  • 511 例有双抗体数据的患者中,308/511(60%)为双阳性,127/511(25%)为双阴性。
  • 良好或中度 EULAR 反应:RF 阳性 vs 阴性 84.6% vs 72.9%(p=0.012);anti-CCP 阳性 vs 阴性 85.2% vs 74.2%(p=0.015)。
  • 平均 CDAI:RF 阳性 vs 阴性 10.8 vs 15.3(p<0.001);anti-CCP 阳性 vs 阴性 10.9 vs 14.3(p=0.002)。
  • Boolean 缓解:RF 阳性 vs 阴性 13.3% vs 4.0%(p=0.008);anti-CCP 阳性 vs 阴性 12.5% vs 6.3%(p=0.096)。

关键数值与推荐

  • EULAR 良好或中度反应率:RF 阳性 84.6% vs 阴性 72.9%(p=0.012);anti-CCP 阳性 85.2% vs 阴性 74.2%(p=0.015)。
  • 平均 CDAI:RF 阳性 10.8 vs 阴性 15.3(p<0.001);anti-CCP 阳性 10.9 vs 阴性 14.3(p=0.002)。
  • Boolean 缓解率:RF 阳性 13.3% vs 阴性 4.0%(p=0.008);anti-CCP 阳性 12.5% vs 阴性 6.3%(p=0.096)。

临床怎么用

  • 对生物制剂初治的 RA 患者,基线 RF 和 anti-CCP 状态可辅助预判静脉阿巴西普 6 个月疗效,血清阳性者可能更受益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the impact of baseline rheumatoid factor (RF) and anticyclic citrullinated peptide (anti-CCP) status on the clinical efficacy of intravenous abatacept in biologic-naïve patients with rheumatoid arthritis (RA) enrolled in the real-world ACTION study. METHODS: Clinical outcomes (European League Against Rheumatism (EULAR) response, mean Clinical Disease Activity Index (CDAI) and Boolean remission) at 6 months were compared by baseline RF and anti-CCP status. RESULTS: Of 672 biologic-naïve patients, RF status was reported in 577 (86%) (412 (71%) positive) and anti-CCP status in 552 (82%) (364 (66%) positive); of 511 patients for whom data were available, 308/511 (60%) were double positive and 127/511 (25%) were double negative. Clinical outcomes were improved with RF-positive or anti-CCP-positive versus RF-negative/anti-CCP-negative status-good or moderate EULAR response: RF: 84.6 vs 72.9%, p=0.012; anti-CCP: 85.2 vs 74.2%, p=0.015; mean CDAI (calculated): RF: 10.8 vs 15.3, p<0.001; anti-CCP: 10.9 vs 14.3, p=0.002; and Boolean remission: RF: 13.3 vs 4.0%, p=0.008; anti-CCP: 12.5 vs 6.3%, p=0.096. Clinical outcomes were also improved with single or double RF-positive/anti-CCP-positive versus double-negative status. CONCLUSIONS: In biologic-naïve patients with RA, RF-positive and/or anti-CCP-positive status is associated with greater efficacy of intravenous abatacept than seronegative status. TRIAL REGISTRATION NUMBER: NCT02109666.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Alten R, Nüßlein HG, Mariette X, et al. Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study. RMD Open. 2017. PMID: 28243468. doi:10.1136/rmdopen-2016-000345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。